Prosensa

^{Priced, Nasdaq: RNA.X}

Late-stage biotech developing treatments for Duchenne muscular dystrophy.

Industry: Health Care

First Day Return: +48.1%

RNA.X

Late-stage biotech developing treatments for Duchenne muscular dystrophy.

IPO News for Prosensa

Agios Pharmaceuticals gains almost 74% in market debut as biotech fever continues 07/24/13
US IPO Recap: Market picks up the pace with ten IPOs, six price below the range 07/01/13
Prosensa prices IPO at $13, the high end of the range 06/27/13

IPO Data
IPO Date	06/27/2013
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$78
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.prosensa.com
Headquarters	Leiden, Netherlands
Founded	2002
Employees at IPO	85

IPO News for Prosensa

Prosensa (RNA.X) Performance